References
- Organization WH. Depression: a global public health concern 2012. Available from: http://www.who.int/mental_health/management/depression/who_paper_depression_wfmh_2012.pdf
- Pampallona S, Bollini P, Tibaldi G, et al. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004;61:714–19
- Pfister WR, Ghosh TK. Orally disintegrating tablets. 2005. Available from: http://www.pharmtech.com/orally-disintegrating-tablets-2?id=&sk=&date=&pageID=5
- Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. Trop J Pharm Res 2009;8:161–72
- Ghosh T, Ghosh A, Prasad D. A review on new generation orodispersible tablets and its future prospective. Int J Pharm Pharm Sci 2011;3:1–7
- Liew K, Peh KK, Tan YTF. Orally disintegrating dosage forms: breakthrough solution for noncompliance. Int J Pharm Pharm Sci 2013;5:4–8
- Frijlink HW. Benefits of different drug formulations in psychopharmacology. Eur Neuropsychopharmacol 2003;13:77–84
- Rasool MA, Rohitas M, Sharma A. A brief overview on fast dissolving drug delivery systems. Int J Drug Disc Herbal Res 2012;3:465–70
- Ratul D, Baquee AA. Pellets and pelletization techniques: a critical review. Int Res J Pharm 2013;4:90–5
- Timmer CJ, Sitsen JA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000;38:461–74
- Anttila SA, Leinonen EV. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev 2001;7:249–64
- Delbressine L, Moonen M, Kaspersen F, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Investig 1998;15:45–55
- Dodd S, Burrows GD, Norman TR. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr B: Biomed Sci Appl 2000;748:439–43
- Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17:10–21
- De Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57:19–25
- Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999;57:607–31
- Al-Omran M, Al-Suwayeh S, El-Helw A, Saleh S. Taste masking of diclofenac sodium using microencapsulation. J Microencapsul 2002;19:45–52
- Shimokawa K-I, Saegusa K, Wada Y, Ishii F. Physicochemical properties and controlled drug release of microcapsules prepared by simple coacervation. Coll Surf B: Biointerfaces 2013;104:1–4
- Nairm JG. 3 Coacervation-phase separation technology. In: Ganderton D, Jones T, McGinity J, eds. Advances in pharmaceutical sciences. vol 7. New York: Academic Press; 1995:93–219
- Convention USP. USP 32 NF 27: United States Pharmacopeia [and] National Formulary, 2009. United States Pharmacopeial Convention. Board of Trustees, Rockville, USA
- Europe Co, Commission EP. European Pharmacopoeia: Council of Europe; 2007
- Food and Drug Administrations. FDA-recommended dissolution methods. Available from: http://www.accessdata.fda.gov/scripts/cder/dissolution/dsp_SearchResults_Dissolutions.cfm
- Pehlivan SB, Yavuz B, Çalamak S, et al. Preparation and in vitro/in vivo evaluation of cyclosporin a-loaded nanodecorated ocular implants for subconjunctival application. J Pharm Sci 2015;104:1709–20
- U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry: orally disintegrating tablets; 2008. Available from: http://www.fda.gov/OHRMS/DOCKETS/98fr/07d-0117-gdl0001.pdf
- Ölmez SS, Vural İ. Advantages and quality control of orally disintegrating tablets. FABAD J Pharm Sci 2009;34:163–76
- Yamamoto Y, Fujii M, Watanabe K-I, et al. Effect of powder characteristics on oral tablet disintegration. Int J Pharm 2009;365:116–21
- Quadir A, Kolter K. A comparative study of current superdisintegrants. 2006. Available from: http://www.pharmtech.com/comparative-study-current-superdisintegrants
- Saha S, Shahiwala AF. Multifunctional coprocessed excipients for improved tabletting performance. Expert Opin Drug Deliv 2009;6:197–208
- Pabari R, Ramtoola Z. Effect of a disintegration mechanism on wetting, water absorption, and disintegration time of orodispersible tablets. J Young Pharm 2012;4:157–63
- DiMasi JA. The value of improving the productivity of the drug development process. Pharmacoeconomics 2002;20:1–10
- Bhalerao K, Gambhire S, Singh S. Taste masking to improve compliance. Int Res J Pharm Appl Sci 2013;3:224–7
- Kulkarni L, Metkari V, Bamane G, et al. Recent trends on achieving taste masking of bitter drug. J Curr Pharma Res 2014;4:1246–57
- Douroumis DD, Gryczke A, Schminke S. Development and evaluation of cetirizine HCl taste-masked oral disintegrating tablets. AAPS Pharm Sci Tech 2011;12:141–51
- Xu J, Bovet LL, Zhao K. Taste masking microspheres for orally disintegrating tablets. Int J Pharm 2008;359:63–9
- Bushra R, Shoaib MH, Aslam N, et al. Formulation development and optimization of ibuprofen tablets by direct compression method. Pak J Pharm Sci 2008;21:113–20
- Shanmugam S. Granulation techniques and technologies: recent progresses. BioImpacts 2015;5:55–63